Integra LifeSciences Holdings (IART) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Integra LifeSciences Holdings stock (IART) is currently trading at $9.55. Integra LifeSciences Holdings PS ratio (Price-to-Sales) is 0.43. Analyst consensus price target for IART is $14.88. WallStSmart rates IART as Underperform.
- IART PE ratio analysis and historical PE chart
- IART PS ratio (Price-to-Sales) history and trend
- IART intrinsic value — DCF, Graham Number, EPV models
- IART stock price prediction 2025 2026 2027 2028 2029 2030
- IART fair value vs current price
- IART insider transactions and insider buying
- Is IART undervalued or overvalued?
- Integra LifeSciences Holdings financial analysis — revenue, earnings, cash flow
- IART Piotroski F-Score and Altman Z-Score
- IART analyst price target and Smart Rating
Integra LifeSciences Holdings
📊 No data available
Try selecting a different time range
Smart Analysis
Integra LifeSciences Holdings (IART) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Integra LifeSciences Holdings (IART) Key Strengths (4)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
98.11% of shares held by major funds and institutions
Supporting Valuation Data
Integra LifeSciences Holdings (IART) Areas to Watch (6)
Company is destroying shareholder value
Revenue declining -1.70%, a shrinking business
Company is losing money with a negative profit margin
Earnings barely growing at 0.40%
Thin operating margins with cost pressures present
Small-cap company with higher risk but more growth potential
Integra LifeSciences Holdings (IART) Detailed Analysis Report
Overall Assessment
This company scores 52/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 4 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.67), Price/Sales (0.43), Price/Book (0.67) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Profit Margin. Growth concerns include Revenue Growth at -1.70%, EPS Growth at 0.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -39.90%, Operating Margin at 12.40%, Profit Margin at -31.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -39.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -1.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Sales) and negatives (Return on Equity, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IART Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IART's Price-to-Sales ratio of 0.43x trades at a deep discount to its historical average of 5.16x (0th percentile). The current valuation is 96% below its historical high of 11.94x set in Dec 2006, and -1% above its historical low of 0.43x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Integra LifeSciences Holdings (IART) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Integra LifeSciences Holdings is in a turnaround phase, with management focused on restoring profitability. Revenue reached 1.6B with 170% decline year-over-year. The company is currently unprofitable, posting a -31.6% profit margin.
Key Findings
Revenue contracted 170% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -31.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Integra LifeSciences Holdings.
Bottom Line
Integra LifeSciences Holdings is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Integra LifeSciences Holdings(IART)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.